Ion in Medical Technology

Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia

... (#1408), "Preclinical Evaluation of the TRPM8 ion Channel Agonist D-3263 for Benign Prostatic ... Dendreon's in-house discovery efforts. It is an ion channel that is triggered by cold temperatures ... agonists including D3263 that activate the TRPM8 ion channel and induce cell death. About ...

Genetic Engineering & Biotechnology News Reports on the Growing Role of Ion-Channel Studies in Global Biotech R&D

... News (GEN). Such interest is not surprising as ion channels play key roles in numerous biological ... ). "Research on ion channels has opened up possibilities for new ways ... are working on a project targeting the Kv4.3 ion channel. The goal of their work is to develop a ...

Ion Mobility Diagnostic Test from Quest Diagnostics is First to Provide Direct Physical Measurement of Lipoprotein Particles, Cardiovascular Disease Indicators, Study Finds

... Chemistry. "Our data suggest that this novel ion mobility-based method offers advantages over ... was to describe and validate the ability of the ion mobility technique to directly and accurately ... and non-HDL particles were determined using the ion mobility technique and correlated with ...

Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia

... (#2041), "Preclinical Validation of the Trp-p8 ion Channel as a Target for Benign Prostatic ... Dendreon's in-house discovery efforts. It is an ion channel that is triggered by cold temperatures ... small molecule agonists that activate the Trp-p8 ion channel and induce cell death. The lead molecule, ...

Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer

... was identified through Dendreon's in-house discovery efforts. It is an ion channel that is triggered by cold temperatures and small-molecule agonists ... small molecule agonists including D3263 that activate the TRPM8 ion channel and induce cell death. About Dendreon Dendreon ...

96-Well Filtration Plate From Varian, Inc. Improves Sensitivity and Precision for Trace Bio-Analysis by LC/MS

... chromatography/mass spectroscopy (LC/MS). Incomplete removal leads to ion suppression (reduced sensitivity) and, over time, degrades the performance ... matrix interferences (over 97% of the phosphatidylcholines are removed). ion suppression is significantly reduced resulting in enhanced sensitivity and ...

Lilly and Glenmark Pharmaceuticals Announce License Agreement

... $3.03 16% to 17% About TRPV1 TRPV1 is a member of the TRPV family of ion channel proteins. It is expressed in human pain pathways and in sensory ... Research on TRPV1 supports the potential for antagonists of this ion channel to be effective in various pain conditions. The goal of the ...

Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R)

... blocker designed to selectively inhibit the rapid firing of nerve cells that causes seizures. It specifically targets the inactivated state of the ion channel, preventing its return to the active state, and thereby reduces repetitive neuronal firing. The efficacy of ESL has been demonstrated in ...

Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial

... of mucus over the surfaces of the air passages in the lungs, removing debris and bacteria. In CF, an inherited disease, a defective gene disrupts ion transport across the epithelial membrane within cells. In the lungs, this leads to a depletion of the airway surface liquid that normally bathes the ...

Discovery's Edge Spring Issue - http://discoverysedge.mayo.edu

... are exploring ways to ensure breathing capability in SCI patients. http://discoverysedge.mayo.edu/de09-1-mssk-sieck-respsci/ Glitches in ion Transporters -- An Unlikely Link Between Kidney Diseases and Glaucoma A tale of coincidence and collaboration: the peculiar case of the kidney ...

Intellect Neurosciences, Inc. Announces Independent Studies on Copper Binding Properties of its Lead Candidate OXIGON(TM)

... Biology at the University of Southern California . Professor Davies added: "Moreover, the so-called 'redox activity' of the bound metal ion can lead to the formation of soluble neurotoxic oligomers as well as fibrillar forms of the protein, which eventually deposit as plaques in the ...

Vical Pandemic Influenza Vaccines Achieve T-Cell Responses and Cross-Clade Reactivity in Humans

... contains the H5 plasmid plus separate plasmids encoding consensus sequences of two highly conserved influenza virus proteins: nucleoprotein (NP) and ion channel protein (M2). The trivalent vaccine was designed to elicit a combination of T-cell and antibody responses against all three proteins. Both ...

Novel Therapeutic Approaches May Transform Treatment and Improve Patient Outcomes in Several Platelet Disorders

... A Therapeutic Platelet Transfusion Strategy Witho u t Routine Prophylactic Transfusion is Feasible and Safe an d Reduces Platelet Transfu s ion Numbers Significantly: Preli m inary Analysis of a Randomi z e d Study in Pa t ients After High-Dose Chemotherapy and Autologous ...

Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network

... Center for Chemical Probe Discovery and Optimization at Scripps Research Institute, Scripps Institute, San Diego, Calif. -- Johns Hopkins ion Channel Center, Johns Hopkins University, Baltimore, Md. -- NIH Chemical Genomics Center, NIH/NHGRI, Rockville, Md. -- University of Kansas ...

Vical Announces Breakthrough for Pandemic Influenza DNA Vaccines With Preliminary Human Data

... contains the H5 plasmid plus separate plasmids encoding consensus sequences of two highly conserved influenza virus proteins: nucleoprotein (NP) and ion channel protein (M2). The trivalent vaccine is designed to elicit a combination of T-cell and antibody responses against all three proteins. Both ...

Duska Therapeutics Licenses Portfolio of Heart Failure Drugs From Duke and Johns Hopkins

... of reactive oxygen radicals and concurrently providing nitric oxide in the failing heart. The therapeutic target is the ryanodine receptor, the ion channel in the heart that provides the calcium necessary for the heart to beat. The investigational drugs are believed to improve calcium cycling in ...

PTC Therapeutics Announces Data Supporting Cough Frequency as a New Outcome Measure in Evaluating Treatments for Cystic Fibrosis

... affects nearly 70,000 adults and children. Patients with CF lack the cystic fibrosis transmembrane conductance regulator (CFTR) protein, a chloride ion channel that maintains proper hydration of epithelial cells in the lungs, pancreas, and liver. Loss of the CFTR protein leads to chronic airway ...

Breakthrough Large Scale Transfection Technology Accelerates Cell-Based Assay Development

... of its ease and speed, transient transfection is increasingly used to replace cloning and recombinant work in a wide range of applications (e.g. ion channel based drug or GPCR screening). The cost-effective MaxCyte ITF Inline Transfection system replaces current preparative transfection ...

HUYA Bioscience Int'l Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China

... along with the Chinese clinical trial data suggest that HBI-3000 may have safety advantages over other anti-AF agents and exhibits broad spectrum ion channel inhibition without pro-arrhythmic activity that suggests it may also be safer to use in treatment of ventricular arrhythmias. HUYA's ...

HUYA Bioscience Int'l Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile

... along with the Chinese clinical trial data suggest that HBI-3000 may have safety advantages over other anti-AF agents and exhibits broad spectrum ion channel inhibition without pro-arrhythmic activity that suggests it may also be safer to use in treatment of ventricular arrhythmias. According to ...

Treatment of First Patient in Phase I Clinical Trial of Bionomics' Anti-Cancer Drug BNC105

... chemistry platform for the discovery of small molecule drugs. ionX(R) is a set of novel technologies for the identification of drugs targeting ion channels for diseases of the central nervous system. For more information about Bionomics, visit http://www.bionomics.com.au About BNC105 ...

Universite de Montreal Researchers Simulate World's Largest Heart Model Using SGI Technology

... to track the effects of a heart disease on the ECG. For instance, many patients with Brugada syndrome have an inheritable disorder on the level of ion channels -- large molecules in the cell membrane that help activate the heart in order to make it beat. It is tempting to believe that these ...

ABR-Affinity BioReagents to Exhibit in the U.S. Pavilion at Medica, November 14 - 17, 2007

... and encompassing Signal Transduction, Vision Research, Neurobiology, Steroids & Hormones, Lipid and Fat Metabolism Regulation, Phosphoproteins, ion Transport and Muscle Biology. We are proud to be able to contribute to life science research in such a significant manner," Ms. Martin stated. ...

Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza

... contains three individual DNA plasmids encoding consensus sequences of two highly-conserved influenza virus proteins -- nucleoprotein (NP) and ion channel protein (M2) -- plus a hemagglutinin (HA) surface protein from the H5N1 influenza virus strain, A/Vietnam/1203/04. The combination is ...

Icagen Terminates Phase III ASSERT Study

... of novel orally-administered small molecule drugs that modulate ion channel targets. Utilizing its proprietary know-how and integrated ... capabilities, Icagen has identified multiple drug candidates that modulate ion channels. The Company's four most advanced programs are: -0- - ...

Icagen to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

... of novel orally-administered small molecule drugs that modulate ion channel targets. Utilizing its proprietary know-how and integrated ... capabilities, Icagen has identified multiple drug candidates that modulate ion channels. The Company is conducting research and development activities, ...

AOP Orphan Pharmaceuticals and Lantibio Announce Positive Phase II Study with Novel Cystic Fibrosis Therapy

... said Dr. Luis Molina, CEO of Lantibio, Inc. About Moli1901 In CF, absence or dysfunction of the chloride channel CFTR causes reduced chloride ion and water transport in respiratory epithelial cells. This results in an altered water content in the airway surface liquid (ASL), leading to thick ...

Independent publication supports the profile of CeNeS phase II compound, CNS 5161

... of neuropathic pain and NMDA antagonists may represent a class of drugs for effective relief of neuropathic pain. CNS 5161 is a blocker of the NMDA ion channel and has completed Phase I and more recently Phase IIa proof of concept clinical trials as a novel compound for the treatment of neuropathic ...

Promising Data on Cognitive Effects of Safinamide in Early Parkinson's Disease

... in inflammatory pain, as well. Newron´s clinical pipeline is supported by a portfolio of early-stage proprietary compounds generated by its ion channel drug discovery platform. Newron is headquartered in Bresso, near Milan, Italy. The company is listed at SWX Swiss Exchange, trading symbol ...